A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men-Reference-Cited by-同舟云学术

A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men

Published:2020-01-20 Issue:7 Volume:9 Page:833-840
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Sakamoto Kei¹,Matsuki Shunji²,Irie Shin²,Uchida Naoki³,Hayashi Nobuya¹,Horiuchi Masato¹,Ren Song⁴

Affiliation:

1. AstraZeneca K.K., Ofuka‐cho Kita‐ku Osaka Japan

2. SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center Fukuoka Japan

3. Department of Pharmacology, Division of Clinical Pharmacology Showa University School of Medicine Tokyo Japan

4. Quantitative Clinical Pharmacology, AstraZeneca Gaithersburg Maryland USA

Funder

AstraZeneca

Amgen

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.775

Reference33 articles.

1. Asthma

2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

3. Japanese guidelines for adult asthma 2017

4. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment

5. Allergic Rhinitis and Sinusitis in Asthma

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects;Frontiers in Pharmacology;2024-07-15

2. Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update;Brazilian Journal of Otorhinolaryngology;2024-05

3. Population Pharmacokinetic Modeling and Exposure–Efficacy and Body Weight–Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma;The Journal of Clinical Pharmacology;2024-04-17

4. Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review;Expert Opinion on Investigational Drugs;2024-01-02

5. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma;Expert Opinion on Drug Discovery;2023-06-30